Loading...
Loading...
Shares of
Emergent Biosolutions Inc were trading higher by more than 1.50 percent early Monday morning after the company
released its preliminary 2015 results, 2016 outlook and a strategic growth plan through 2020.
Emergent Biosolutions said that it expects to earn $1.54 to $1.63 per share for the full year 2015 on revenue of $520 million to $525 million. Meanwhile, Wall Street analysts were expecting the company to earn $1.51 per share on sales of $524.80 million.
Emergent Biosolutions also guided its full year 2016 sales to a range of $600 million to $630, topping Wall Street's expectations of $544.32 million.
Looking forward to 2020, Emergent Biosolutions is expecting an annual revenue run-rate of $1 billion with 6 products in clinical or advanced development and at least 3 being dual use.
Finally, Emergent Biosultions added that it has an even longer term vision of "protecting and enhancing" 50 million lives by 2020.
"Having successfully implemented our 2012-2015 growth plan and delivered financial results in excess of our expectations, we are well-positioned for continued success and growth," Daniel J. Abdun-Nabi, President and CEO of Emergent Biosolutions said.
"Looking ahead we will remain focused on addressing the growing public health threats market and will build on our momentum to achieve our newly established 2020 goals."Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
